Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral naltrexone-accelerated versus buprenorphine-assisted withdrawal for transition to extended-release naltrexone
IRCT20250123064499N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in opioid use disorder (OUD) comparing Accelerated withdrawal management with oral naltrexone with Withdrawal management with sublingual buprenorphine (2 arms). Primary endpoint: Injection of first dose of extended-release naltrexone. Started Apr 2025; status: completed.
02
Drugs
naltrexonebuprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on IRCT20250123064499N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250123064499N1.